Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04299490 · ClinicalTrials.gov registry record · Phase 2
Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT04299490: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04299490 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 148 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04299490, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) evaluate whether experimental SCD and/or SF alter resting or pain-evoked receptor binding potential in brain regions associated with pain inhibition; 2) examine whether SCD and/or SF alters the analgesic response and abuse liability profile of a study medication; and 3) determine whether receptor binding potentials in brain regions of interest are associated with study medication analgesia and abuse liability. The investigators will also evaluate the extent to which associations differ by sleep condition or sex.
Interventions
- BEHAVIORAL Sleep Fragmentation
- DRUG Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
- BEHAVIORAL Sleep Continuity Disruption
- BEHAVIORAL Undisturbed Sleep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04299490
The ClinicalTrials.gov registry entry for NCT04299490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sleep Fragmentation is the first listed.
NCT04299490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04299490 about?
NCT04299490 is a clinical study titled "Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug". The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) eval...
What is the current status of trial NCT04299490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2020-11-11. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT04299490?
The interventions under investigation include: Sleep Fragmentation (BEHAVIORAL), Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) (DRUG), Sleep Continuity Disruption (BEHAVIORAL), Undisturbed Sleep (BEHAVIORAL).
Who is sponsoring clinical trial NCT04299490?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.